HLA-I diversity and tumor mutational burden by comprehensive next-generation sequencing as predictive biomarkers for the treatment of non-small cell lung cancer with PD-(L)1 inhibitors.
Lung Cancer
; 170: 1-10, 2022 08.
Article
in En
| MEDLINE
| ID: mdl-35689896
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Carcinoma, Non-Small-Cell Lung
/
Lung Neoplasms
Type of study:
Prognostic_studies
/
Risk_factors_studies
Limits:
Humans
Language:
En
Journal:
Lung Cancer
Journal subject:
NEOPLASIAS
Year:
2022
Document type:
Article
Country of publication:
Ireland